News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Angiotech Pharmaceuticals, Inc. Loss Widens As Royalties Slow
July 30, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TORONTO July 30 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO) said its second-quarter loss widened on Friday as royalty payments from its marketing partners slowed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
Ventus “Recalibrates” to Support Mid-Stage Trials
July 16, 2025
·
159 min read
·
BioSpace Editorial Staff
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
·
1 min read
·
Heather McKenzie
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
